Tango Therapeutics, Inc. (TNGX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$23.34-16.43%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tango Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	636,727
EPS	—	-0.38
Annual ending 2026-12-31
Revenue	—	6.06M
EPS	—	-1.423
Annual ending 2027-12-31
Revenue	—	3.13M
EPS	—	-1.681

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress clinical trials of vopimetostat, especially with RAS(ON) inhibitors	A primary condition in Tango Therapeutics, Inc.'s published investment case. The stated target is Continue advancing trials with positive data and regulatory progress.	Improving	Trial progress stalls or negative data emerges within next year	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Control operating losses near or below -$49 million per quarter	Despite losses, management aims to control operating costs.	Under Pressure	Operating losses worsen beyond -$49 million per quarter in FY26	Operating income: $-59.785M FY2026-Q2; GAAP. Published target: Operating income no worse than -$49 million per quarter. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-59,785,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1a63d12e-665d-4249-9a99-68c8393ee83b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain sufficient capital to fund clinical trials and operations	The company secured $600 million in capital to fund operations.	Intact	Failure to secure capital leading to operational constraints	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.68

$-1.52 → $-1.68 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.52	$2,855,090	11 / 11
2026-07-25	$-1.52	$2,855,090	11 / 11
2026-07-26	$-1.52	$2,855,090	11 / 11
2026-07-27	$-1.52	$2,855,090	11 / 11
2026-07-28	$-1.52	$2,855,090	11 / 11
2026-07-29	$-1.49	$3,488,889	10 / 7
2026-07-30	$-1.52	$2,855,090	11 / 11
2026-07-31	$-1.49	$3,488,889	10 / 7
2026-08-01	$-1.49	$3,488,889	10 / 7
2026-08-02	$-1.52	$2,855,090	11 / 11
2026-08-03	$-1.52	$2,855,090	11 / 11
2026-08-04	$-1.52	$2,855,090	11 / 11
2026-08-05	$-1.49	$3,488,889	10 / 7
2026-08-06	$-1.52	$2,855,090	11 / 11
2026-08-08	$-1.52	$2,855,090	11 / 11
2026-08-09	$-1.52	$2,855,090	11 / 11
2026-08-10	$-1.49	$3,488,889	10 / 7
2026-08-12	$-1.49	$3,488,889	10 / 7
2026-08-13	$-1.49	$3,488,889	10 / 7
2026-08-14	$-1.49	$3,488,889	10 / 7
2026-08-15	$-1.49	$3,488,889	10 / 7
2026-08-16	$-1.49	$3,488,889	10 / 7
2026-08-17	$-1.49	$3,488,889	10 / 7
2026-08-18	$-1.49	$3,488,889	10 / 7
2026-08-19	$-1.49	$3,488,889	10 / 7
2026-08-20	$-1.66	$3,140,000	11 / 8
2026-08-21	$-1.66	$3,140,000	11 / 8
2026-08-22	$-1.66	$3,140,000	11 / 8
2026-08-23	$-1.66	$3,140,000	11 / 8
2026-08-24	$-1.66	$3,140,000	11 / 8
2026-08-25	$-1.66	$3,140,000	11 / 8
2026-08-26	$-1.66	$3,140,000	11 / 8
2026-08-27	$-1.66	$3,140,000	11 / 8
2026-08-28	$-1.66	$3,140,000	11 / 8
2026-08-29	$-1.66	$3,140,000	11 / 8
2026-08-30	$-1.66	$3,140,000	11 / 8
2026-08-31	$-1.66	$3,140,000	11 / 8
2026-09-01	$-1.66	$3,140,000	11 / 8
2026-09-02	$-1.66	$3,140,000	11 / 8
2026-09-03	$-1.66	$3,140,000	11 / 8
2026-09-04	$-1.66	$3,140,000	11 / 8
2026-09-05	$-1.66	$3,140,000	11 / 8
2026-09-06	$-1.66	$3,140,000	11 / 8
2026-09-07	$-1.66	$3,140,000	11 / 8
2026-09-08	$-1.66	$3,140,000	10 / 7
2026-09-09	$-1.70	$3,488,889	10 / 7
2026-09-10	$-1.70	$3,488,889	10 / 7
2026-09-11	$-1.70	$3,488,889	10 / 7
2026-09-12	$-1.70	$3,488,889	10 / 7
2026-09-13	$-1.70	$3,488,889	9 / 7
2026-09-14	$-1.70	$3,488,889	9 / 7
2026-09-15	$-1.70	$3,488,889	9 / 7
2026-09-16	$-1.70	$3,488,889	9 / 7
2026-09-17	$-1.70	$3,488,889	9 / 7
2026-09-18	$-1.70	$3,488,889	9 / 7
2026-09-19	$-1.70	$3,488,889	9 / 7
2026-09-20	$-1.70	$3,488,889	9 / 7
2026-09-21	$-1.70	$3,488,889	9 / 7
2026-09-22	$-1.70	$3,488,889	9 / 7
2026-09-23	$-1.70	$3,488,889	9 / 7
2026-09-24	$-1.70	$3,488,889	9 / 7
2026-09-25	$-1.70	$3,488,889	9 / 7
2026-09-26	$-1.70	$3,440,000	9 / 7
2026-09-27	$-1.70	$3,440,000	9 / 7
2026-09-28	$-1.70	$3,440,000	9 / 7
2026-09-29	$-1.70	$3,440,000	9 / 7
2026-09-30	$-1.70	$3,440,000	9 / 7
2026-10-01	$-1.70	$3,440,000	9 / 7
2026-10-02	$-1.70	$3,440,000	9 / 7
2026-10-03	$-1.70	$3,440,000	9 / 7
2026-10-04	$-1.70	$3,440,000	9 / 7
2026-10-05	$-1.70	$3,440,000	9 / 7
2026-10-06	$-1.70	$3,440,000	9 / 7
2026-10-07	$-1.70	$3,440,000	9 / 7
2026-10-08	$-1.70	$3,440,000	9 / 7
2026-10-09	$-1.70	$3,440,000	9 / 7
2026-10-10	$-1.70	$3,440,000	9 / 7
2026-10-11	$-1.70	$3,440,000	9 / 7
2026-10-12	$-1.70	$3,440,000	9 / 7
2026-10-13	$-1.70	$3,440,000	9 / 7
2026-10-14	$-1.70	$3,440,000	9 / 7
2026-10-15	$-1.70	$3,440,000	9 / 7
2026-10-16	$-1.67	$3,127,273	9 / 7
2026-10-17	$-1.67	$3,127,273	9 / 7
2026-10-18	$-1.67	$3,127,273	10 / 8
2026-10-19	$-1.67	$3,127,273	10 / 8
2026-10-20	$-1.67	$3,127,273	10 / 8
2026-10-21	$-1.67	$3,127,273	10 / 8
2026-10-22	$-1.67	$3,127,273	10 / 8
2026-10-23	$-1.67	$3,127,273	10 / 8
2026-10-24	$-1.68	$3,127,273	10 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	3
2026-06-01	11	3
2026-07-01	12	1
2026-08-01	12	1
2026-09-01	12	1
2026-10-01	12	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausOct 23 · prior Apr 27

$40.00 → $55.00+37.5%

$0$30.25$60.50

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Progress clinical trials of vopimetostat, especially with RAS(ON) inhibitorsDirect metric needs a verified mapping
Control operating losses near or below -$49 million per quarterPublished status: Under Pressure
Maintain sufficient capital to fund clinical trials and operationsDirect metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-33.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tango Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk clinical-stage biotechnology company, with value tied to research progress rather than current earnings. Its multi-year view is still at a watch stage: clinical evidence has advanced, but key trial plans remain in progress and recent results have been weak.

What's priced into Tango Therapeutics, Inc.

The valuation model points to a premium versus peers, while its confidence is low and the expectations gap is substantial. The evidence suggests some value is being assigned to future pipeline potential, but the premium is not clearly supported by current financial performance.

What the fundamentals likely do

Near term, TNGX is likely to remain loss-making as it funds research and clinical programs; its latest reported quarterly net loss widened year over year, while research spending increased. Cash and marketable securities rose in the reported balance and management expects the June balance to fund its current operating plan, but the recent earnings miss and consecutive-miss pattern make the next results a key risk.

What Tango Therapeutics, Inc. hinges on

The multi-year thesis depends on advancing vopimetostat toward a planned Phase 3 pancreatic cancer trial and delivering on broader pipeline milestones. Near term, a guidance cut or weaker employment data could add pressure, while continued strength from major healthcare companies could support the sector backdrop. The October clinical response and progression-free survival results are encouraging evidence, but they do not establish completion of the planned trial.